Up 1,530% in 2020, Is Vaxart Still a Buy?
While much of the discussion around COVID-19 vaccines has lately focused on the difficulties of shipping and storing them at temperatures that would make a polar bear shiver, Vaxart (NASDAQ: VXRT) has been steadily working on developing one that would eliminate a lot of the logistical complexity. The company's coronavirus vaccine candidate comes in tablet form, and is shelf-stable at room temperature.
Investors rewarded the effort by driving Vaxart's shares up by more than 1,500% last year, from $0.35 to $5.71. With gains like that in the rear-view mirror, could there still be upside for investors who buy shares today?
Image Source: Getty Images
Source Fool.com
